Avantium Provides Crystal16™ to All Research Sites of Sanofi-Aventis
14 September 2006
Amsterdam, The Netherlands – September 4, 2006 - Avantium Technologies announced today an agreement with Sanofi-Aventis for the deployment of its proprietary Crystal16™ at all research & development centers of Sanofi-Aventis. Sanofi-Aventis has selected the Crystal16™ for the enhancement of its crystallization research capabilities, to increase the experimental throughput of its scientists and to be able to perform crystallization experiments on a smaller scale.
"We are pleased to provide our Crystal16™ platform to the global Sanofi-Aventis research organization", commented Guus Scheefhals, Chief Business Officer at Avantium, "this agreement validates Avantium's strategy to provide high-value added tools next to its services business."
The Crystal16™ is a novel and proprietary platform for performing parallel crystallization experiments in 1-ml reactors. The Crystal16™ can be used for a range of applications in pharmaceutical and chemical research, such as solubility measurements, improving the understanding of crystallization processes and the generation of crystals for product characterization. Users of the Crystal16™ are capable of running 16 experiments in parallel, using minimum quantities of precious starting materials while retrieving maximum knowledge about the crystallization process and solid-state of their product. More information can be found at www.crystal16.com.
